| Popis: |
Tables depicting dose modifying factors (DMF) at surviving fractions of 0.37% and 0.1% survival were calculated for each treatment combination. A, G7, E2 and R10 cells grown in 2D or 3D conditions grown in the presence of VEGF [(+) VEGF], or the absence of VEGF [(-) VEGF] followed by radiation at indicated doses (0-5 Gy). DMF at 0.37 and 0.1 for (+) VEGF compared to (-) VEGF conditions. B, G7, E2 and R10 cells grown in 2D or 3D conditions were treated with DMSO or erlotinib followed by radiation treatment as in A. DMF at 0.37 and 0.1 for erlotinib compared to DMSO conditions. C, G7 and E2 cells were incubated with MK2206, Erlotinib and their combination for 2D conditions or {plus minus}VEGF and MK2206 for 3D conditions and irradiated as in A. DMF calculated for treatments v DMSO for 2D cells; (-) VEGF, (-) VEGF plus MK2206, or (+) VEGF plus MK2206 v (+) VEGF for 3D cells. D, E2 cells were transfected with either siScramble (siScr) or siRNAs against Akt1 and Akt3 for 48 hrs followed by radiation treatment as in A. DMF calculated for siAkt vs siScr. E, Cell lysates from E2 cells transfected with siRNA against DNA-PKcs (siDNAPKcs) or siScr for 48 hours followed by radiation treatment as in A. DMF calculated for treatments v DMSO_siScr. |
